

July 01, 2024

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001

BSE Scrip Code: 524743

Dear Sir,

Reg : Press Release – Fischer Medical Ventures Limited (formerly known as Fischer Chemic Limited), has announced a groundbreaking global partnership with Singapore-based innovators Nervotec Pte Ltd (Nervotec).

We enclose a Press Release regarding **“Fischer MVL is pleased to seal the strategic partnership with Nervotec to market their paradigm shifting technology globally”**, for dissemination.

Thanking you,
Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)
RAVINDRAN Digitally signed by
RAVINDRAN GOVINDAN
GOVINDAN Date: 2024.07.01 12:32:38
+05'30'

RAVINDRAN GOVINDAN
CHAIRMAN & MANAGING DIRECTOR





CIN L24231MH1993PLC288371

Registered Office : 104, First Floor Raghuleela Mega Mall, Behind Poisar Depot, Kandivali West Mumbai, Maharashtra, 400067
Corporate Office : Level 5, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006

Fischer Medical Ventures Limited (formerly known as Fischer Chemic Limited), has announced a groundbreaking global partnership with Singapore-based innovators Nervotec Pte Ltd (Nervotec).

Fischer Medical Ventures Limited (Fischer MVL) through its Wholly owned Subsidiary - Time Medical International Ventures (India) Private Limited is renowned for its pioneering efforts in manufacturing high-quality Magnetic Resonance Imaging (MRI) systems in India, is pleased to announce the successful partnering with Singapore-based innovators Nervotec Pte Ltd (Nervotec) to enable Blood Pressure, Hemoglobin and HbA1C screening through camera-enabled device. This collaboration marks a significant stride towards revolutionizing healthcare screening through advanced, contactless video-based vital signs monitoring technology. Fischer MVL is pleased to seal the strategic partnership with Nervotec to market their paradigm shifting technology globally.

- Nervotec is a Singapore-based company that empowers predictive healthcare via its contactless solution without wearables. Nervotec's innovative solution uses remote photoplethysmography (rPPG) technology and artificial intelligence to measure physiological biomarkers such as heart rate, heart rate variability, respiration rate, oxygen saturation, stress scores and even blood pressure just from a person's face using any camera-enabled device like smartphone, laptop, or tablet. Users simply had to look at their camera-enabled device and within minutes, Nervotec's algorithms will analyze his/her vitals, making wearables or invasive procedures redundant. Clinically validated in Singapore, Nervotec's process is fast, accurate, and cost effective, a ground-breaking solution to enable large scale screening for early detection and intervention.
- Continuing to push the boundaries, **Nervotec made a first-in-the-world breakthrough achievement recently by including clinically validated hemoglobin measurement (to measure Anaemia and detect Thalassemia) and HbA1C (average glucose level over a period) measurements as part of its comprehensive health monitoring capabilities. What used to require vials of blood & significant time to analyse, Nervotec made it possible with its contactless technology and give results within few minutes.**
- The partnership between Fischer MVL and Nervotec signifies a transformative leap in healthcare screening capabilities, offering innovative solutions that are accessible, efficient, and comprehensive. This collaboration is poised to redefine healthcare delivery by making advanced diagnostic technologies more accessible and impactful worldwide.
- This strategic alliance combines Fischer MVL's expertise in medical devices and solutions, robust resources, and strategic network worldwide with Nervotec's cutting-edge technologies that promise to redefine healthcare delivery globally.



Commenting on the announcement.

Mr. Ravindran Govindan, Chairman & Managing Director of Fischer MVL, expressed his enthusiasm about the collaboration: "We are elated to partner with Nervotec, a pioneer and leader in contactless vital signs monitoring that will redefine healthcare delivery worldwide. Not everyone has wearables, but most of us have a camera phone to enable Nervotec's technology for regular monitoring of their own health and support mass screening faster and more cost effective. We are excited about the potential of rPPG technology beyond HbA1C to detect irregular heartbeats and detection of cardiovascular disease, combined with blood pressure and blood sugar levels to determine the overall health of individuals worldwide. Nervotec's solutions complement our portfolio of medical devices and diagnostic solutions, and will create great value for our customers and stakeholders."

Mr. Jonathan Lau, Co-founder and CEO of Nervotec, emphasized the transformative potential of their technology, "With the high prevalence of undetected conditions such as hypertension and diabetes, we believe Nervotec's innovative solution can truly make a difference in the well-being of billions of people globally. By identifying health risks before they escalate, Nervotec's technology empowers individuals, healthcare providers, and employers to take timely action. This partnership with Fischer MVL enables us to expand our reach and deliver impactful health insights across various sectors, from workplace safety to personalized healthcare."

Disclaimer:

This investor release is not an offer to sell any securities or a solicitation to buy any securities of Fischer Medical Ventures Limited (formerly known as Fischer Chemic Ltd) (the "company") or its subsidiaries (together with the company, the "group"). Certain statements in this document may be forward looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "or" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intention. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Investor Release, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. **FISCHERMVL** will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward- looking statements to reflect subsequent events or circumstances.